TRENDING TOPICS
3286 articles found for "investing"
S&P 500 software and services stocks are down 20% year-to-date in 2026 as AI disruption fears hammer established tech. Here's what's happening and how to position your portfolio.
Figma reports its first earnings as a public company with Q4 2025 revenue of $303.8 million, up 40% year-over-year, a 136% net dollar retention rate at a 10-quarter high, and 2026 full-year guidance of $1.37 billion implying 30% growth.
S&P 500 Q4 2025 earnings are growing at a blended 13.2%, the fifth consecutive double-digit growth quarter, with 74% of companies beating estimates by an average of 7.2%.
SEC Chair Paul Atkins' Project Crypto initiative marks the end of the enforcement-era approach to digital assets, opening institutional capital markets to blockchain and creating a fundamentally new investment landscape.
Analog Devices reported Q1 fiscal 2026 revenue of $3.16 billion, up 30% year-over-year, with EPS of $2.46 beating estimates by $0.13. The company's Q2 guidance of $3.5 billion came in nearly $300 million above consensus.
Garmin reported Q4 2025 EPS of $2.79, crushing the $2.40 estimate, while revenue hit $2.12B — a 17% year-over-year gain. The company raised its dividend 17% and issued guidance for 9% growth in 2026.
Devon Energy reported Q4 revenue of $4.12 billion, beating estimates, but EPS of $0.82 was in line and down from $1.16 a year ago. The 2026 outlook highlights tariff risks and OPEC uncertainty.
Applied Materials beat every estimate with $2.38 EPS and $7.01 billion in revenue as its gross margin hit a 25-year high of 49.1%, proving that AI's true beneficiaries are the companies building the physical infrastructure.
The S&P 500 energy sector has surged 14% year-to-date to become the market's undisputed leader while technology stocks struggle, marking the most significant sector rotation since 2022.
Berkshire Hathaway's new CEO endorses Kraft Heinz's surprise decision to pause its planned separation, signaling Abel's willingness to deviate from Buffett's apparent desire to exit the position.
Dexcom beat Q4 revenue and earnings estimates with 13.1% growth to $1.26 billion, and new clinical data shows that patients using both GLP-1 drugs and continuous glucose monitors achieve significantly better outcomes than those using either alone.
Wealthfront's stock has fallen from $14 at its December IPO to $8.20, erasing $800 million in market value despite record revenue of $93.2 million and $92.8 billion in platform assets. The decline signals a broader fintech valuation reckoning.